论文部分内容阅读
目的探讨甲状腺不典型腺瘤的辅助诊断指标。方法采用组织芯片免疫组化法检测40例甲状腺滤泡癌、40例甲状腺腺瘤和40例甲状腺不典型腺瘤组织中β-半乳糖凝集素3(β-galectin-3)和上皮钙黏蛋白(E-cadherin)的表达。结果甲状腺不典型腺瘤组织中β-galectin-3阳性表达率低于甲状腺滤泡癌(52.5%vs.75.0%),但高于甲状腺腺瘤的30.0%(P<0.05);甲状腺不典型腺瘤组织中E-cadherin阳性表达率高于甲状腺滤泡癌(75.0%vs.30.0%),但低于甲状腺腺瘤的87.5%(P<0.05)。结论联合测定β-galectin-3和E-cadherin表达可初步诊断甲状腺不典型腺瘤和甲状腺滤泡癌。
Objective To investigate the diagnosis of atypical thyroid adenoma. Methods Tissue microarray immunohistochemistry was used to detect the expression of β-galectin-3 and E-cadherin in 40 cases of thyroid follicular carcinoma, 40 cases of thyroid adenoma and 40 cases of thyroid atypical adenoma. (E-cadherin) expression. Results The positive rate of β-galectin-3 in thyroid atypical adenoma was lower than that in thyroid follicular carcinoma (52.5% vs. 75.0%), but higher than thyroid adenoma (30.0%, P <0.05) The positive rate of E-cadherin in tumor tissue was higher than that in thyroid follicular carcinoma (75.0% vs. 30.0%), but lower than that in thyroid adenoma (87.5%, P <0.05). Conclusions The combined detection of β-galectin-3 and E-cadherin can be used to diagnose atypical thyroid adenoma and thyroid follicular carcinoma.